Sort   by:  
 Page size 
MetabolomicsMetabolite assay of T cells that are antigen-specially activated by viscoelastic synthetic antigen presenting cells

Adoptive T cell receptor (TCR)–based immunotherapy offers a powerful strategy to target solid tumors. However, the physical properties of the antigen-presenting interface regulate T cell metabolic programming remains poorly defined. Here we develop synthetic viscoelastic activating cells (SynVAC)...

2026-09-03 | MTBLS15444 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (CAR-T Metabolites)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14640 | MetaboLights
MetabolomicsPharmacological Targeting of ALDH1a2 in Dendritic Cells Enhances Antigen Presentation, T Cell Activation and Anti-tumor immunity
Dendritic cell (DC) vaccines have been proposed as cancer immunotherapies due to their role as crucial antigen-presenting cells that regulate T cell functions. Despite considerable efforts to optimize ex vivo priming of DCs, DC vaccines have rarely been successful, suggesting the presence of unknown...
2025-11-03 | MTBLS10389 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (Glucose Tracer)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14641 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14634 | MetaboLights
MetabolomicsSpaceM reveals metabolic states of single cells

A growing appreciation of the importance of cellular metabolism and revelations concerning the extent of cell-cell heterogeneity demand metabolic characterization of individual cells. We present SpaceM, an open-source method for in situ single-cell metabolomics that detects >100 metabolites fr...

2021-05-11 | MTBLS78 | MetaboLights
MetabolomicsTargeting secreted MDK-mediated tryptophan/kynurenine metabolism enhances DLL3 CAR T therapy for SCLC

Small cell lung cancer (SCLC) exhibits profound immunometabolic suppression that impairs antigen presentation and constrains immunotherapy efficacy. Through integrated multi-omics analyses of primary human SCLC tumors, we identified midkine (MDK) as a dominant tumor-secreted driver of immune evas...

2026-03-23 | MTBLS14116 | MetaboLights
MetabolomicsMesenchymal stromal cells secretome restores bioenergetic and redox homeostasis in human proximal tubule cells after ischemic injury

BACKGROUND: Ischemia/reperfusion injury (IRI) is the leading cause of acute kidney injury (AKI). The current standard of care focuses on supporting kidney function, stating the need for more efficient and targeted therapies to enhance repair. Mesenchymal Stromal Cells (MSCs) and ...

2023-10-16 | MTBLS6279 | MetaboLights
MetabolomicsThe Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells
Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...
2016-11-07 | MTBLS337 | MetaboLights
MetabolomicsSingle-cell metabolic fingerprints discover a cluster of circulating tumor cells with distinct metastatic potential

Circulating tumor cells (CTCs) are recognized as direct seeds of metastasis. However, CTC count may not be the 'best' indicator of metastatic risk because their heterogeneity is generally neglected. In this study, we develop a molecular typing system to predict colorectal cancer metastasis potent...

2023-08-21 | MTBLS5028 | MetaboLights
Sort   by:  
 Page size